UNSPSC 51312812: Methdilazine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T0GSO02UEZ, chemically known as 10h-phenothiazine, 10-((1-methyl-3-pyrrolidinyl)methyl)-, monohydrochloride but more generally known as methdilazine hydrochloride, which bears US NIH Compound Identifier 14676. European Medicines Agency schedules Methdilazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03213MIG.

UNSPSC 51312812 Methdilazine hydrochloride is a Commodity code nominally identifying a specific pharmaceutical compound, but recent state and local solicitations tagged under this code do not involve methdilazine directly. Instead, the opportunities reveal purchasing activity for naloxone (an opioid antagonist), generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The code appears to be a mismatch or placeholder for broader pharmaceutical procurement rather than a narrowly targeted drug acquisition. The issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances, reflecting the diversity of public health and employee benefit procurement across jurisdictional levels.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 (response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 on January 20, 2026 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, with awarded vendors taking effect July 1, 2026 through authorized wholesalers including Cencora, Cardinal Health, and Morris & Dickson. The mismatch between the nominal UNSPSC code and the actual pharmaceutical categories being purchased suggests the code does not reliably signal relevant opportunities for methdilazine-specific vendors.